Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Puromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | NPEPPS | P55786 | 12/20 | 0.99 |
| ▸ | ANPEP | P15144 | 10/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL29713430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL677485 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL31237590 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL4317 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL2348795 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL5067276 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL9724067 | 0.99 | SMN1; SMN2 (0.99) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL24206459 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL21306559 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL18190282 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414677-B2 | Methods and compositions for performing continuous directed evolution | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200278343-A1 | DIRECT VISUALIZATION OF INTEGRATED STRESS RESPONSE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| US-20190153472-A1 | METHODS AND COMPOSITIONS FOR PERFORMING CONTINUOUS DIRECTED EVOLUTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-05-23 | — | — | US | disclosed |
| US-8207093-B2 | Producing libraries; including high salt post translational incubation step | THE GENERAL HOSPITAL CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1712623-B1 | Selection of proteins using RNA-protein fusions | GEN HOSPITAL CORP (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100162416-A1 | Multi-stage stem cell carcinogenesis | STEMLIFELINE, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010037134-A2 | MULTI-STAGE STEM CELL CARCINOGENESIS | STEMLIFELINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-1151143-B1 | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS | GEN HOSPITAL CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080058217-A1 | Selection of proteins using RNA-protein fusions | GENERAL HOSPITAL CORPORATION, THE | 2008-03-06 | — | — | US | disclosed |
| US-7270950-B2 | Nucleic acid-protein fusions and methods of making and selecting fusions | THE GENERAL HOSPITAL CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2000047775-A9 | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS | GEN HOSPITAL CORP (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6281344-B1 | A DNA COVELENTLY BOUND TO PROTEIN THROUGH PUROMYCIN, THAT IS ADDED TO THE GROWING PEPTIDE CHAIN BY CATALYTIC ACTIVITY OF A RIBOSOMAL PEPTIDYL TRANSFERASE; FOR ISOLATING PROTEINS WITH DESIRED PROPERTIES FROM POOLS OF RANDOM AMINO ACID SEQUENCES | THE GENERAL HOSPITAL CORPORATION | 2001-08-28 | — | — | US | disclosed |
| US-6261804-B1 | USING POPULATION OF RNA, EACH WITH REGULATORY SEQUENCES, PROTEIN CODING SEQUENCE AND PEPTIDE ACCEPTOR AT 3' END; IN VITRO TRANSLATING CODING SEQUENCES; THEN INCUBATING UNDER HIGH SALT CONDITIONS TO FORM FUSIONS AND PROTEIN LIBRARY | THE GENERAL HOSPITAL CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6258558-B1 | USING RNA WHICH HAS REGULATORY SEQUENCES LINKED TO PROTEIN CODING SEQUENCE AND BONDED TO PEPTIDE ACCEPTOR, IN VITRO TRANSLATING TO PRODUCE FUSIONS, SELECTING BY BINDING OR ACTIVITY, THEN GENERATING DNA | THE GENERAL HOSPITAL CORPORATION | 2001-07-10 | — | — | US | disclosed |
| US-6214553-B1 | LIBRARYOF PROTTEIN ENCODING RNA MOLECULES WHICH ARE COVALENTLY BONDED AT THEIR 3'ENDS TO A NON-RNA PAUSE SEQUENCE WHICH CAUSES A RIBOSOME TO SLOW OR STOP ITS RATE OF TRANSLATION | MASSACHUSETTS GENERAL HOSPITAL | 2001-04-10 | — | — | US | disclosed |
| US-6207446-B1 | MICROCHIP ARRAY OF IMMOBILIZED SINGLE-STRANDED NUCLEIC ACIDS WHICH ARE HYBRIDIZED TO RNA-PROTEIN FUSIONS; FUSIONS ARE RNA COVALENTLY BONDED TO 3' END OF PROTEIN THROUGH A PEPTIDE ACCEPTOR; PROTEIN IS ENCODED BY RNA; CYCLES OF SCREENING | THE GENERAL HOSPITAL CORPORATION | 2001-03-27 | — | — | US | disclosed |
| WO-2000047775-A1 | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0971946-A1 | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998031700-A1 | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-07-23 | — | — | WO | disclosed |
| US-5283065-A | Active spherical granules containing microcrystalline cellulose; compressible spherical granules containing mono- or di-saccharide optionally including same or different active material | AMERICAN CYANAMID COMPANY (US) | 1994-02-01 | — | — | US | disclosed |